September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Anti-viral efficiency of NCX4240 (iota-carrageenan) eye drops against Adenoviruses (AdV) causing epidemic keratoconjunctivitis (EKC)
Author Affiliations & Notes
  • Brigitte Duquesroix
    Nicox, Sophia-Antipolis, France
  • Sabine Nakowitsch
    Marinomed, Wien, Austria
  • Footnotes
    Commercial Relationships   Brigitte Duquesroix, Nicox (E); Sabine Nakowitsch, Marinomed (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5406. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brigitte Duquesroix, Sabine Nakowitsch; Anti-viral efficiency of NCX4240 (iota-carrageenan) eye drops against Adenoviruses (AdV) causing epidemic keratoconjunctivitis (EKC). Invest. Ophthalmol. Vis. Sci. 2016;57(12):5406. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : There is no treatment available for epidemic keratoconjunctivitis caused by AdVs on the market. As new treatment option, the anti-viral efficiency of iota-carrageenan against these viruses was evaluated. Iota-carrageenan is highly effective against respiratory viruses including rhinoviruses as shown in-vitro, in-vivo, and in clinical studies. The goal of this study was to test the newly developed eye drop formulation NCX4240 (3.2 mg/ml iota-carrageenan) against three of the most common AdV strains known to be responsible for EKC (strains 8, 19 and 37). In parallel, two other marketed eye-drop formulations were evaluated for their anti-viral effect against these viruses: Vismed© (1.8 mg/ml hyaluronic acid) and Carmellose© (5 mg/ml carboxymethylcellulose (CMC)).

Methods : A549 cells were infected with AdV 8, 19, and 37 and cultivated in the presence of serial dilutions of the three different eye drop formulations. The inhibition of virus replication was evaluated by the relative amount of generated AdV protein detected by immunostaining. The anti-viral activity of the three compounds was determined by the lowest concentration needed for 50% inhibition of virus replication (IC50).

Results : Iota-carrageenan in the tested eye drop formulation NCX4240 is anti-virally active against all three AdV viruses (8, 19 and 37) tested with IC50 concentrations <20 µg/ml. In contrast, the two other products containing either hyaluronic acid or CMC did not show any anti-viral activity at the highest concentrations tested, 300 µg/ml and 400 µg/ml, respectively.
IC50 concentrations needed for inhibition of AdV [µg/ml] were for Iota-carrageenan (NCX4240): AdV8 = 19.7, AdV19 = 11.4 and AdV37 = 11.3, for hyaluronic acid (Vismed®): >300 for the 3 strains and for CMC (Carmellose®): >400 for the three strains.

Conclusions : The newly developed product NCX4240 is anti-virally effective against AdV8, 19 and 37 at concentrations which are 160 times lower than that present in the final product (3.2 mg/ml). Other marketed products (Vismed® and Carmellose®) do not have any anti-viral effect. Based on these encouraging results we suggest testing NCX4240 as a treatment in AdV infected patients in a clinical trial.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.